Teva Passes Its Check-Up

0
40

The turnaround during Teva Pharmaceutical Industries stays on schedule.

The general drug hulk reported third-quarter sales of $4.5 billion and practiced gain of 68 cents a share. While both total were down significantly from a year earlier, a gain figure surfaced expectations interjection to deeper cost cuts than analysts had anticipated. Teva also increasing the full-year superintendence for distinction and giveaway money flow.

That…

LEAVE A REPLY

Please enter your comment!
Please enter your name here